Tanvex BioPharma, Inc. (6541.TW)

TWD 64.1

(7.19%)

Gross Profit Summary of Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc.'s latest annual gross profit in 2023 was 59.7 Million TWD , down -1270.33% from previous year.
Tanvex BioPharma, Inc.'s latest quarterly gross profit in 2024 Q1 was -71.72 Million TWD , up 10.22% from previous quarter.
Tanvex BioPharma, Inc. reported a annual gross profit of -19.34 Million TWD in annual gross profit 2022, down -645.01% from previous year.
Tanvex BioPharma, Inc. reported a annual gross profit of 3.55 Million TWD in annual gross profit 2021, up 2382.52% from previous year.
Tanvex BioPharma, Inc. reported a quarterly gross profit of -71.72 Million TWD for 2024 Q1, up 10.22% from previous quarter.
Tanvex BioPharma, Inc. reported a quarterly gross profit of -79.89 Million TWD for 2023 Q4, down -2041.46% from previous quarter.

Annual Gross Profit Chart of Tanvex BioPharma, Inc. (2023 - 2013)

Historical Annual Gross Profit of Tanvex BioPharma, Inc. (2023 - 2013)

Year	Gross Profit	Gross Profit Growth
2023	59.7 Million TWD	-1270.33%
2022	-19.34 Million TWD	-645.01%
2021	3.55 Million TWD	2382.52%
2020	143 Thousand TWD	100.07%
2019	-215.96 Million TWD	-51.27%
2018	-142.76 Million TWD	-7.58%
2017	-132.7 Million TWD	-12.87%
2016	-117.57 Million TWD	-74.49%
2015	-67.38 Million TWD	0.0%
2014	- TWD	0.0%
2013	- TWD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	-72.49 Million TWD	99.39%
2024 Q1	-71.72 Million TWD	10.22%
2023 Q4	-79.89 Million TWD	-2041.46%
2023 Q2	11.04 Million TWD	-72.76%
2023 FY	-265.13 Million TWD	-1270.33%
2023 Q3	4.11 Million TWD	-62.74%
2023 Q1	40.53 Million TWD	1528.29%
2022 Q2	703 Thousand TWD	103.91%
2022 Q4	-2.83 Million TWD	-461.07%
2022 Q3	786 Thousand TWD	11.81%
2022 Q1	-17.99 Million TWD	-646.75%
2022 FY	-19.34 Million TWD	-645.01%
2021 Q4	3.29 Million TWD	1175.97%
2021 FY	3.55 Million TWD	2382.52%
2021 Q2	-57.79 Million TWD	4.11%
2021 Q1	-60.27 Million TWD	0.0%
2021 Q3	258 Thousand TWD	100.45%
2020 Q4	- TWD	-100.0%
2020 Q1	- TWD	0.0%
2020 Q2	- TWD	0.0%
2020 Q3	143 Thousand TWD	0.0%
2020 FY	143 Thousand TWD	100.07%
2019 Q4	- TWD	0.0%
2019 Q1	- TWD	0.0%
2019 FY	-215.96 Million TWD	-51.27%
2019 Q2	- TWD	0.0%
2019 Q3	- TWD	0.0%
2018 Q3	- TWD	0.0%
2018 FY	-142.76 Million TWD	-7.58%
2018 Q2	- TWD	0.0%
2018 Q1	- TWD	0.0%
2018 Q4	- TWD	0.0%
2017 Q1	- TWD	0.0%
2017 Q2	- TWD	0.0%
2017 FY	-132.7 Million TWD	-12.87%
2017 Q3	- TWD	0.0%
2017 Q4	- TWD	0.0%
2016 FY	-117.57 Million TWD	-74.49%
2016 Q2	- TWD	0.0%
2016 Q3	- TWD	0.0%
2016 Q4	- TWD	0.0%
2016 Q1	- TWD	0.0%
2015 Q2	- TWD	0.0%
2015 Q4	- TWD	0.0%
2015 Q3	- TWD	0.0%
2015 Q1	- TWD	0.0%
2015 FY	-67.38 Million TWD	0.0%
2014 Q4	- TWD	0.0%
2014 Q2	- TWD	0.0%
2014 Q1	- TWD	0.0%
2014 FY	- TWD	0.0%
2014 Q3	- TWD	0.0%
2013 FY	- TWD	0.0%

Peer Gross Profit Comparison of Tanvex BioPharma, Inc.

Name	Gross Profit	Gross Profit Difference
Apex Biotechnology Corp.	531.11 Million TWD	88.759%
Sinphar Pharmaceutical Co.,Ltd.	1.09 Billion TWD	94.529%
Panion & Bf Biotech Inc.	912.56 Million TWD	93.458%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	757.3 Million TWD	92.117%
GenMont Biotech Incorporation	177.33 Million TWD	66.335%
Abnova (Taiwan) Corporation	173.91 Million TWD	65.672%
Adimmune Corporation	410.93 Million TWD	85.472%
Polaris Group	-137.9 Million TWD	143.293%
Energenesis Biomedical CO.,LTD.	5.22 Million TWD	-1042.166%
UnicoCell Biomed Co., Ltd.	17.89 Million TWD	-233.581%
PELL Bio-Med Technology Co. Ltd.	-26.14 Million TWD	328.389%